IPO registrations (S-1, F-1) · Registrants
LUMOS PHARMA, INC.
- SEC CIK
- 1126234 · filings on EDGAR ↗
- Name on the registration
- NEWLINK GENETICS CORP
- Former names
- NEWLINK GENETICS CORP (2002–2020)
- Registration
- Form S-1, first filed 2010-12-21, last 2011-11-10; 1 initial registration, 7 amendments
- Outcome
- Final prospectus filed 2011-11-14; declared effective 2011-11-10
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 4200 MARATHON BLVD., SUITE 200, Austin, TX 78756
- EIN
- 42-1491350
- EDGAR entity type
- operating
- Insiders and CEO pay
- LUMOS PHARMA, INC. on the corporate pages
Offering terms
- Final price
- $7.00 per share (424B4 filed 2011-11-14, an initial public offering)
- Shares sold
- 6,200,000
- Gross proceeds
- $43,400,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol NLNK
- Lead underwriters
- Stifel (2,867,500 shares); Canaccord Genuity (1,937,500 shares); Baird (930,000 shares); Cantor Fitzgerald (465,000 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: NEWLINK GENETICS CORPORATION EXACT (EIN (EXACT, as the state registration reports it))
- Form 5500 plan sponsor: LUMOS PHARMA, INC. EXACT (EIN (EXACT))
- SEC filer: LUMOS PHARMA, INC. EXACT (CIK (EXACT))
- Person page: James E Flynn Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther))
Filings 11
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2010-12-21 | S-1 | S-1 (registration) | NEWLINK GENETICS CORP | 0001047469-10-010516 ↗ |
| 2011-02-28 | S-1/A | S-1/A (amendment) | NEWLINK GENETICS CORP | 0001047469-11-001496 ↗ |
| 2011-03-18 | S-1/A | S-1/A (amendment) | NEWLINK GENETICS CORP | 0001047469-11-002351 ↗ |
| 2011-09-14 | S-1/A | S-1/A (amendment) | NEWLINK GENETICS CORP | 0001047469-11-008009 ↗ |
| 2011-10-04 | S-1/A | S-1/A (amendment) | NEWLINK GENETICS CORP | 0001047469-11-008354 ↗ |
| 2011-10-26 | S-1/A | S-1/A (amendment) | NEWLINK GENETICS CORP | 0001047469-11-008688 ↗ |
| 2011-11-08 | S-1/A | S-1/A (amendment) | NEWLINK GENETICS CORP | 0001047469-11-009169 ↗ |
| 2011-11-10 | S-1/A | S-1/A (amendment) | NEWLINK GENETICS CORP | 0001047469-11-009373 ↗ |
| 2011-11-10 | EFFECT | EFFECT (declared effective) | NEWLINK GENETICS CORP | 9999999995-11-003221 ↗ |
| 2011-11-14 | 424B4 | 424B4 (final prospectus) | NEWLINK GENETICS CORP | 0001047469-11-009408 ↗ |
| 2013-01-04 | EFFECT | EFFECT (declared effective) | NEWLINK GENETICS CORP | 9999999995-13-000131 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2011-11-10 | S-1/A | registration statement | $5.00 | - | - | 0 | primary document; price line | document ↗ | ||
| 2011-11-14 | 424B4 | final prospectus | $7.00 | 6,200,000 | $43,400,000 | Nasdaq NLNK | 4 | primary document; price sentence, shares headline, proceeds table, underwriting table 4, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Alexander Sarah | Director | 2 | 2011 | ||
| Edick Paul R | Director | 12 | 2011–2017 | ||
| Link Charles J. Jr. | Director,Officer; Director,Officer,TenPercentOwner | Chairman of the Board and CEO; Chairman of the Board & CEO | 59 | 2011–2019 | |
| LINK GORDON H JR | Officer | Chief Financial Officer | 18 | 2011–2014 | |
| Lundquist David J. | Director | 5 | 2011–2012 | ||
| Lynn Kenneth | Officer; Other | Exec VP of Bus Developement; Exec VP of Bus Development | 4 | 2011–2012 | |
| Raffin Thomas A. | Director | 23 | 2011–2024 | ||
| Ramsey William J. | Officer | Quality Assurance Officer | 27 | 2011–2015 | |
| Saluri Joseph | Director | 14 | 2011–2017 | ||
| Stine Seed Farm, Inc. | TenPercentOwner | 4 | 2011–2017 | ||
| Talarico Ernest III | Director | 21 | 2011–2019 | ||
| Vahanian Nicholas N. | Officer | Pres and Chief Medical Officer; Pres, Chief Medical Officer; President; President, Chief Medical Offic; President Chief Medical Office | 31 | 2011–2019 | |
| Zoth Lota S. | Director | 19 | 2012–2024 | ||
| Wiley Brian | Officer | Chief Commercial Officer; VP of Business Development | 17 | 2013–2018 | |
| Langren Carl W. | Officer | Chief Financial Officer; Principal Accounting Officer | 27 | 2013–2021 | |
| HENNEMAN JOHN B III | Officer | Chief Administrative Officer; EVP, Chief Financial Officer | 16 | 2014–2018 | |
| Pucci Paolo | Director | 4 | 2015–2018 | ||
| Kennedy Eugene P. | Officer | Chief Medical Officer | 14 | 2017–2021 | |
| JOHNSON CHAD ALLEN | Director | 10 | 2018–2024 | ||
| Sherman Matthew L | Director | 4 | 2018–2019 | ||
| Lawley Lori D | Officer | Chief Financial Officer; Principal Accounting Officer | 18 | 2018–2024 | |
| POWERS BRADLEY J | Officer | General Counsel; Principal Executive Officer | 12 | 2019–2024 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | TenPercentOwnerOther | 2 | 2020–2021 | ||
| Deerfield Mgmt III, L.P. | TenPercentOwnerOther | 2 | 2020–2021 | ||
| Deerfield Private Design Fund III, L.P. | TenPercentOwnerOther | 2 | 2020–2021 | ||
| Flynn James E | TenPercentOwnerOther | 2 | 2020–2021 | person page Fuzzy | |
| Cunningham Emmett | Director | 2 | 2020 | ||
| Hawkins Richard J | Director,Officer | Chief Executive Officer | 13 | 2020–2024 | |
| LALANDE KEVIN M. | Director | 14 | 2020–2024 | ||
| McCracken Joseph S | Director | 10 | 2020–2024 | ||
| McKew John C. | Officer | Chief Scientific Officer | 19 | 2020–2024 | |
| van Es-Johansson An | Director | 6 | 2021–2024 | ||
| Schuchart Aaron | Officer | Chief Business Officer | 8 | 2021–2024 | |
| Karpf David B | Officer | Chief Medical Officer | 4 | 2021–2023 | |
| Pitukcheewanont Pisit Duke | Officer | Chief Medical Officer | 5 | 2024 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | NEWLINK GENETICS CORPORATION | State business registries | EIN (EXACT, as the state registration reports it) | |
| Form 5500 plan sponsor | LUMOS PHARMA, INC. | EIN (EXACT) | ||
| Form D issuer | Lumos Pharma, Inc. | Form D private offerings | name and state | |
| Person page | James E Flynn | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther) | |
| SEC filer | LUMOS PHARMA, INC. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.